Stock BRKR BRUKER CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bruker Corporation

Equities

BRKR

US1167941087

Advanced Medical Equipment & Technology

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
80.97 USD +0.47% Intraday chart for Bruker Corporation +4.13% +10.19%
Apr. 26 Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference CI
Apr. 22 Bruker Agrees Signs Asset Purchase Deal With NanoString Technologies MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 7,849 8,288 12,725 10,053 10,170 11,768 - -
Enterprise Value (EV) 1 7,977 8,400 12,991 10,627 10,964 12,252 12,196 11,902
P/E ratio 40.5 x 53.1 x 46.4 x 34.3 x 25.3 x 34.2 x 25.9 x -
Yield 0.31% 0.3% 0.19% 0.29% 0.27% 0.25% 0.25% 0.25%
Capitalization / Revenue 3.79 x 4.17 x 5.26 x 3.97 x 3.43 x 3.61 x 3.39 x 3.19 x
EV / Revenue 3.85 x 4.23 x 5.37 x 4.2 x 3.7 x 3.75 x 3.51 x 3.23 x
EV / EBITDA 19.9 x 23.2 x 24.9 x 19.1 x 17.9 x 18.9 x 15.6 x 13.5 x
EV / FCF 56.8 x 35.7 x 68.2 x 73.2 x 45.1 x 26.1 x 23.2 x -
FCF Yield 1.76% 2.8% 1.47% 1.37% 2.22% 3.84% 4.31% -
Price to Book 8.57 x 8.58 x 12 x 9 x - 6.38 x 4.85 x -
Nbr of stocks (in thousands) 153,992 153,108 151,655 147,083 138,411 145,335 - -
Reference price 2 50.97 54.13 83.91 68.35 73.48 80.97 80.97 80.97
Announcement Date 3/27/20 2/16/21 2/11/22 2/9/23 2/13/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,073 1,988 2,418 2,531 2,964 3,263 3,475 3,687
EBITDA 1 401.3 361.9 521.9 556.5 614.1 649 781.1 881.6
EBIT 1 364 317.2 470.2 505.6 546.3 570.1 694.6 777.3
Operating Margin 17.56% 15.96% 19.45% 19.98% 18.43% 17.47% 19.99% 21.08%
Earnings before Tax (EBT) - - - - - - - -
Net income 1 197.2 157.8 277.1 296.6 427.2 338.4 447.7 -
Net margin 9.51% 7.94% 11.46% 11.72% 14.41% 10.37% 12.88% -
EPS 2 1.260 1.020 1.810 1.990 2.900 2.370 3.130 -
Free Cash Flow 1 140.4 235 190.4 145.2 243.2 470 525.6 -
FCF margin 6.77% 11.82% 7.87% 5.74% 8.2% 14.4% 15.13% -
FCF Conversion (EBITDA) 34.99% 64.94% 36.48% 26.09% 39.6% 72.42% 67.3% -
FCF Conversion (Net income) 71.2% 148.92% 68.71% 48.95% 56.93% 138.89% 117.42% -
Dividend per Share 2 0.1600 0.1600 0.1600 0.2000 0.2000 0.2004 0.2004 0.2003
Announcement Date 3/27/20 2/16/21 2/11/22 2/9/23 2/13/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 608.9 683.5 595 588.4 638.9 708.4 685.3 681.9 742.8 854.5 728.7 762 831.9 940.5 781.6
EBITDA 1 138.4 156.6 128.2 110 155.3 163 153.8 118.8 163.4 178.1 124 134.4 175.5 217.7 148.9
EBIT 1 125.4 143.8 115.8 97.7 143.2 148.9 139.4 104.1 148.3 154.5 99.02 121.1 155.9 196 131.7
Operating Margin 20.59% 21.04% 19.46% 16.6% 22.41% 21.02% 20.34% 15.27% 19.96% 18.08% 13.59% 15.89% 18.74% 20.84% 16.85%
Earnings before Tax (EBT) - - - - - - - - - - - - - - -
Net income 1 87.1 75.7 61.6 49.5 88.1 97.4 76.5 57.1 88.1 205.5 49.1 62.3 102.3 124.7 -
Net margin 14.3% 11.08% 10.35% 8.41% 13.79% 13.75% 11.16% 8.37% 11.86% 24.05% 6.74% 8.18% 12.3% 13.26% -
EPS 2 0.5700 0.5000 0.4100 0.3300 0.5900 0.6600 0.5200 0.3900 0.6000 1.410 0.3600 0.4800 0.6850 0.8500 -
Dividend per Share 2 0.0400 0.0400 - - - 0.0500 0.0500 - - 0.0500 0.0501 0.0502 0.0503 0.0505 -
Announcement Date 11/1/21 2/11/22 5/4/22 8/3/22 11/3/22 2/9/23 5/4/23 8/3/23 11/2/23 2/13/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 128 113 266 574 793 484 428 134
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.32 x 0.3114 x 0.5097 x 1.031 x 1.292 x 0.7463 x 0.5478 x 0.1521 x
Free Cash Flow 1 140 235 190 145 243 470 526 -
ROE (net income / shareholders' equity) 27% 22% 31.6% 31.9% 30.1% 25.4% 25.9% 25.3%
ROA (Net income/ Total Assets) 10% 7.16% 9.58% 9.61% 9.67% 9.59% 10.9% -
Assets 1 1,963 2,205 2,892 3,087 4,416 3,527 4,112 -
Book Value Per Share 2 5.950 6.310 7.000 7.590 - 12.70 16.70 -
Cash Flow per Share 2 1.360 2.160 1.850 1.840 2.380 3.640 3.620 -
Capex 1 73 98.2 92 129 107 128 106 -
Capex / Sales 3.52% 4.94% 3.8% 5.11% 3.61% 3.92% 3.04% -
Announcement Date 3/27/20 2/16/21 2/11/22 2/9/23 2/13/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Bruker Corporation

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
80.97 USD
Average target price
89.4 USD
Spread / Average Target
+10.41%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
BRUKER CORPORATION Stock Bruker Corporation
+10.19% 11.77B
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.07% 219B
DANAHER CORPORATION Stock Danaher Corporation
+6.59% 183B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.26% 133B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+26.57% 108B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+13.35% 52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-0.62% 48.2B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-0.93% 40.37B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+11.54% 39.35B
RESMED, INC. Stock ResMed, Inc.
+26.76% 32.03B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. BRKR Stock
  4. Financials Bruker Corporation